West Pharma SVP converts RSUs, withholds shares for tax

West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares.

Rhea-AI Filing Summary

West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. He acquired 82.299 common shares through the exercise or conversion of restricted stock units, which convert into common stock on a one-for-one basis.

Following this conversion, 27.809 common shares were disposed of at 248.26 per share to cover tax obligations through a tax-withholding disposition, rather than an open-market sale. After these transactions, his direct common stock holdings totaled 307.398 shares, and he held 247.899 restricted stock units directly. A prior grant of 329 restricted stock units vests in four equal annual installments, including dividend equivalents.

Insider Trade Summary

82.299 shares exercised/converted

Exercise 3 txns

Insider Poussot Rodolphe Jean

Role SVP, Strategy & Corporate Dev

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	82.299	$0.00	$0.00
Exercise	Common Stock	82.299	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	27.809	$248.26	$7K

Holdings After Transaction: Rst. Stock Unit — 247.899 contracts (Direct); Common Stock — 307.398 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units convert into common stock on a one-for-one basis.
2. F2. On February 18, 2025, the reporting person was granted 329 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

FAQ

What insider transactions did West Pharmaceutical (WST) report for Rodolphe Jean Poussot?

Rodolphe Jean Poussot reported exercising 82.299 restricted stock units into common shares and a related tax-withholding disposition of 27.809 common shares at 248.26 per share. These transactions reflect equity compensation activity, not open-market buying or selling.

Did the West Pharmaceutical (WST) executive buy or sell shares on the open market?

The executive did not report open-market trades. He converted 82.299 restricted stock units into common shares, then 27.809 shares were withheld as a tax-withholding disposition at 248.26 per share, which is a non-market transaction tied to equity compensation.

How many West Pharmaceutical (WST) shares does Rodolphe Jean Poussot hold after the Form 4?

After the reported transactions, he directly holds 307.398 shares of common stock and 247.899 restricted stock units. These amounts reflect the net effect of the restricted stock unit conversion and the related tax-withholding share disposition on the reporting date.

What are the terms of the restricted stock unit grant to the West Pharmaceutical (WST) executive?

He was granted 329 restricted stock units, vesting in four equal annual installments, plus dividend equivalents. Each restricted stock unit converts into one share of common stock upon vesting, aligning a portion of his compensation with West Pharmaceutical’s equity over several years.

What does transaction code F mean in this West Pharmaceutical (WST) Form 4?

Transaction code F indicates shares were used to pay exercise price or tax liabilities. In this case, 27.809 common shares were disposed of at 248.26 per share to satisfy tax obligations arising from the restricted stock unit conversion, not as an elective open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poussot Rodolphe Jean

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Strategy & Corporate Dev

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		M		82.299	A	(1)	335.207	D
Common Stock	02/18/2026		F		27.809	D	$248.26	307.398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	02/18/2026		M			82.299	(2)	(2)	Common Stock	82.299	$0	247.899	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On February 18, 2025, the reporting person was granted 329 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

	/s/ Louis Lalli, as an agent for Rodolphe J. Poussot	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.